anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cough reflex measured by capsaicin Inhalation Challenge will follow Dicpinigaitis performed at 1 and 3 months. Solutions prepared to make a stock solution of 0.01 Mol diluted with physiologic saline to yield 11 doubling concentrations from 0.98 to 1,000 uMol/L. Final diluted capsaicin concentrations are: 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1000 uMol/L. Then, place 1 ml of the first concentration into nebulizer. Subjects inhale single breath of capsaicin aerosol. Single breaths are delivered in ascending order, with normal saline randomly interspersed to increase blindness, until two or more coughs (C2) and five or more coughs (C5) are reached. The different concentrations are delivered at 2 minute intervals.
In 2015, there were near 787,000 patients diagnosed with lung cancer in China. And in the very same year, 631,000 lung cancer patients died of the disease. Lung cancer still causes most cancer related death in here. Approximately 85% of lung cancer is non-small cell lung cancer (NSCLC) compared with small cell lung cancer (\~15%) pathologically. NSCLC include squamous cell NSCLC, adenocarcinoma and large cell carcinoma. Although there are therapies developed to treat the condition, patients with advanced squamous-cell (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options in China. Hence, we developed a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor monoclonal antibody (SCT-I10A) which inhibits the interaction between PD-1 and its ligands results in the reactivation of active T cell and finally leads to caner immunotherapy. We are now carrying out a phase 3 clinical trial to determine whether SCT-I10A plus docetaxel surpass docetaxel monotherapy with previously treated squamous-cell NSCLC patients. As designed in the protocol, 360 eligible subjects would be randomized into two arms in a ratio of 2:1. 240 subjects would be treated with SCT-I10A plus docetaxel in the experimental arm while 120 subjects would be treated with placebo plus docetaxel in the active comparator arm. Both of these arms will be treated with maintenance therapy after planed treatments. Our primary endpoint is overall survival, secondary endpoints are PFS, OSR, ORR, DOR, DCR and other efficacy and safety index.
Background: Bleeding is a frequent complication during surgery. The peri-operative administration of blood products, including packed red blood cells, thrombocytes and fresh frozen plasma (FFP), is often deemed necessary. Beside the expenses of blood products these products carry risks of infection, allergic reaction and immune-modulation. Therefore the transfusion of allogenic blood products mandates strategies to optimize the clinical decision to transfuse. Bleeding during surgery is a dynamic process; it can happen within minutes and result not only in major blood loss, but also in coagulation aberrations. The indication for a transfusion should be based on reliable coagulation studies. Traditional coagulation studies require up to 1 hour. Therefore, the decision to administer FFP is usually made in the absence of any data. Point of care testing of prothrombin time ensures that a major parameter of coagulation is readily available in the operation theatre within 3 minutes. It is fast, easy to perform, inexpensive and may enable physicians to rationally determine the need for FFP. Objective: To determine the effectiveness of point of care coagulation testing of prothrombin time to reduce the administration of FFP. Methods: Patient and assessor blind, single center randomized controlled parallel group trial in 220 patients aged between 18 and 90 years undergoing major surgery (any type, except cardiac surgery and liver transplant) with an estimated blood loss during surgery exceeding 20% of the calculated normal total blood volume or a requirement of FFP according to the judgment of treating surgeons or anesthesiologists. Patients will be randomized to usual care plus point of care coagulation testing or usual care alone without point of care testing. Primary endpoint will be the relative risk to receive any FFP peri-operatively. Significance: Point of care coagulation testing in the operation theatre may reduce the administration of fresh frozen plasma considerably, which in turn may decrease costs and complications usually associated with the administration of allogenic blood products.
OBJECTIVES: Our research aims to construct machine learning prediction models to identify patients proned to recurrence after inverted papilloma (IP) surgery and guide their follow-up treatment.
METHODS: This study collected 210 patients underwent IP resection surgery at a university hospital from January 2010 to December 2023. Six machine learning algorithms including ExtraSurvivalTrees (EST), GradientBoostingSurvivalAnalysis (GBSA), RandomSurvivalForest (RSF), SurvivalSVM, Coxnet and Coxph, were used to construct the prediction models. Shapley Additive Explanations (SHAP) values were used to explain the importance of various features in predicting IP recurrence.
RESULTS: We found that the recurrence rate of IP patients is 20.00%, with a median recurrence time of 35.5 months. Multivariate Cox regression analysis identified mild or moderate dysplasia as an independent risk factor for recurrence. The EST model performs the best in predicting postoperative recurrence of IP, with C-index of 0.968 and 0.878 in the training and testing sets. SHAP emphasizes five important predictive factors for recurrence, including bone defects, orbital involvement, smoking, no processing of tumor attachment sites and drinking.
CONCLUSIONS: To our knowledge, this is the first study to use multiple ML models to predict postoperative recurrence of IP. The EST model has the best predictive performance, with SHAP emphasizing several key predictive factors for IP recurrence. This study emphasizes the practicality of machine learning algorithms in predicting IP clinical outcomes, providing valuable insights into the potential for improving clinical decision-making.
The efficacy of VIGIV against vaccinia virus in a mouse-tail lesion model was assessed. A range of doses of VIGIV and a previously licensed VIG were compared for their ability to reduce pox formation in this model.

Using this model, it was demonstrated that VIGIV exerted an in vivo protective effect against vaccinia infection when compared to a negative control. In addition, when using the mouse-tail lesion model with two different strains of vaccinia virus, it was observed that the protective effect of VIGIV appeared similar to that of the previously licensed VIG and a CBER reference standard.

A single study in rabbits has demonstrated increased corneal scarring upon intramuscular vaccinia immune globulin administration in vaccinia keratitis (7).

Since VIGIV is a product of human origin, secondary pharmacodynamics, safety pharmacology and pharmacodynamic drug interactions were not investigated in animals.
A compound is used to conceal a medication or supplement to be given to an animal. The compound includes water as a carrier solvent, at least one hydrogenated oil, at least one emulsifier and a preservative. One or more additional ingredients may also be optionally added to the compound. These ingredients include anti-caking agents, viscosifiers, flavorings, coloring agents and binders. In any event, the embodiments may have a peel strength to paper of about 0.079 lbs./inch or a peel strength to itself of about 0.079 lbs./inch. It may have a tensile strength of about 0.33 psi and a compressive strength of about 2.02 psi. The invention also includes a method of administering a medication/supplement to an animal by forming a layer of the compound around the medication/supplement.
A composition containing stem cells for the treatment of inflammatory diseases, including post-traumatic inflammatory responses after damage or an injury. Use of trehalose for the production of specific drugs. The invention is based on the use of stem cells, especially mesenchymal stem cells derived from bone marrow or from adipose tissue or limbal stem cells treated with trehalose. The invention is further based on the use of trehalose for the supportive treatment of inflammatory diseases and post-traumatic responses while treating any of these diseases with a composition comprising mesenchymal stem cells. Trehalose may also serve as a solution, powder or tablet for the supportive treatment of inflammatory diseases in the treatment of these diseases by administering stem cells. The composition is produced by a process which involves separating stem cells from a biological material and culturing stem cells in a culture medium.
Indocyanine green (ICG) angiography has become an established technology in many surgical fields, as well as in neurosurgery with the first application of microscope-integrated indocyanine angiography, which dates to 2003.1 More recently we observed the integration of ICG into endoscopic visualization (e-ICG), which resulted in different applications during the endoscopic endonasal approach ranging from evaluation of intranasal flap perfusion to differentiation of pituitary neuroendocrine tumors from normal gland or even as a predictive factor of postoperative visual function after expanded approaches.2-8 A 49-year-old woman was admitted to our hospital after a 1-year history of amenorrhea and radiologic finding of an intrasellar lesion. The clinical picture was compatible with a nonfunctioning pituitary neuroendocrine tumor, and the mass was completely removed by means of an endoscopic endonasal approach with intraoperative use of e-ICG (Video 1). A 25 mg intravenous bolus of ICG was injected immediately after completion of the sphenoid phase of the approach. ICG was visualized with a dedicated ICG-integrated endoscope coupled to an IMAGE1 S camera system set on Chroma enhancement mode. Near-infrared excitation of fluorescence (780-820 nm) was obtained using a D-light P Cold Light Fountain. At follow-up, the patient experienced resolution of her symptoms, without residues or relapses on control magnetic resonance. This case sheds light on some possible applications and advantages of e-ICG, including visualization of internal carotid arteries before the sellar opening, individuation of the pituitary gland, its distinction from the adenomatous tissue, and the possible evaluation of its degree of compression.
The experimental group will receive the same program of exercises given to the control group, 45 minutes of Pilates exercises (such as back twists, single leg circles, standing splits, alternate toe touches, ball leg lifts).The Pilates exercises will be aimed at improving lower-limb strength, flexibility, and coordination, and they will be performed on a mat, using a medical ball. The focus will be on maintaining core contraction, spinal and pelvic alignment, and respiration rhythm. Ten repetitions of Pilates exercises will be performed, with a 2-minute rest period between repetitions.
The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
Tissue-engineered bio-active cardiac constructs (BACCS) are described. These constructs are prepared by combining a suspension of isolated cells with a suitable support such as an extra-cellular filament or matrix. The isolated-cell component of the constructs is prepared from mammalian cardiac tissue, or from cells that differentiate into cardiac tissue. Extra-cellular filaments and/or matrices are prepared from naturally-occurring or synthetic polymers and may be biodegradable or non-biodegradable, depending on the application. Bio-active cardiac constructs are prepared in suspension culture using a defined, serum-free medium. Bio-active cardiac constructs are functionally and morphologically similar to intact cardiac tissue and may be used as tissue equivalents for research or drug testing applications, as well as in surgical applications for the treatment of heart disease.
The therapeutic target of COVID-19 is focused on the control of inflammation and the prevention of fibrosis. Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms observed in rheumatic and fibrotic disorders. In this work, the investigators explored the therapeutic effects of both, in addition to dexamethasone, on the early treatment of patients with severe COVID-19. The hospital stay, quick COVID-19 severity index (qCSI) and admission to the ICU were statistically significantly lower when the patients were treated with collagen-PVP or pirfenidone, compared to the controls treated with dexamethasone alone. Furthermore, only collagen-PVP normalized serum glucose at discharge. Since the intracellular mechanism of action of pirfenidone is partially known, it was performed a whole human genome microarray assay with total RNA isolated from fibroblast and macrophage cultures treated with collagen-PVP. Ingenuity Pathway Analysis showed that cell cycle, inflammation, and cell surface-extracellular matrix interaction could be regulated by the collagen-PVP copolymer, by down-regulation of pro-inflammatory cytokines, such as IL-6 and -8, while Th2 anti-inflammatory response signaling could be up-regulated. Additionally, down-regulation of some of the genes involved in nitric oxide production by inducible nitric oxide synthase showed a possible control for JAK, in the IFN-γ pathway, allowing the possibility of controlling inflammation through the JAK/STAT pathway, as has been observed for pirfenidone and other immunomodulators, such as ruxolitinib. In summary, once again, collagen-PVP and pirfenidone have demonstrated to favor inflammatory control and stand out as a possible therapy for inflammatory disorders derived from viral or microorganism infections.
This study highlights the agronomic potential of rare introgressions, as demonstrated by a major QTL for powdery mildew resistance on chromosome 7D. It further shows evidence for inter-homoeologue recombination in wheat. Agriculturally important genes are often introgressed into crops from closely related donor species or landraces. The gene pool of hexaploid bread wheat (Triticum aestivum) is known to contain numerous such "alien" introgressions. Recently established high-quality reference genome sequences allow prediction of the size, frequency and identity of introgressed chromosome regions. Here, we characterise chromosomal introgressions in bread wheat using exome capture data from the WHEALBI collection. We identified 24,981 putative introgression segments of at least 2 Mb across 434 wheat accessions. Detailed study of the most frequent introgressions identified T. timopheevii or its close relatives as a frequent donor species. Importantly, 118 introgressions of at least 10 Mb were exclusive to single wheat accessions, revealing that large populations need to be studied to assess the total diversity of the wheat pangenome. In one case, a 14 Mb introgression in chromosome 7D, exclusive to cultivar Pamukale, was shown by QTL mapping to harbour a recessive powdery mildew resistance gene. We identified multiple events where distal chromosomal segments of one subgenome were duplicated in the genome and replaced the homoeologous segment in another subgenome. We propose that these examples are the results of inter-homoeologue recombination. Our study produced an extensive catalogue of the wheat introgression landscape, providing a resource for wheat breeding. Of note, the finding that the wheat gene pool contains numerous rare, but potentially important introgressions and chromosomal rearrangements has implications for future breeding.
PURPOSE: A composition for immunological reaction suppression including placenta originated stem cells is provided to be used for an acute or chronic Graft Versus Host Disease therapeutic agent. CONSTITUTION: A composition for immunological reaction suppression includes placenta originated stem cell as an active ingredient. The mesenchyme stem cell is originated from chorionic plate film of placenta. The mesenchyme stem cell expresses CD105, CD44, CD73 or CD90 cell surface antigens which are lobus medius indicators. The composition induces reduction of S phase and G2/M(mitotic) phase and increase of cell cycle G0/G1 phase of lymphocyte cell. The composition reduces CD69+ cell. The composition suppresses immune reaction for the transplanted organs or cells. The transplanted organs or cells are isotransplant or xenograft. The composition is used for treatment or prevention of autoimmune diseases or rejection of internal organ transplant reaction. The autoimmune disease is GVHD(graft-versus-host disease). The composition is manufactured in the injection form.
Initially, all patients will receive 3L/min of oxygen for 10 minutes. Than, patients in this arm will receive 30L/min of High Flow Nasal Oxygen for 15 minutes and subsequently 70 L/min for another 15 minutes.
Electrical storm (ES) is a life-threatening condition of recurrent ventricular arrhythmias (VA) in a short period of time. Percutaneous stellate ganglion blockade (SGB) is frequently used - however the efficacy is undefined. The objective of our systematic review was to determine the efficacy of SGB in reducing VA events and mortality among patients with ES. A search of Medline, EMBASE, Scopus, CINAHL and CENTRAL was performed on February 29, 2024 to include studies with adult patients (≥ 18 years) with ES treated with SGB. Our outcomes of interest were VA burden pre- and post-SGB, and in-hospital/30-day mortality. A total of 553 ES episodes in 542 patients from 15 observational studies were included. Treated VAs pre- and post-SGB were pooled from eight studies including 383 patients and demonstrated a decrease from 3.5 (IQR 2.25-7.25) to 0 (IQR 0-0) events (p = 0.008). Complete resolution after SGB occurred in 190 of 294 patients (64.6%). Despite this, in-hospital or 30-day mortality remained high occurring in 140 of 527 patients (random effects prevalence 22%). Repeat SGB for recurrent VAs was performed in 132 of 490 patients (random effects prevalence 21%). In conclusion, observational data suggests SGB may be effective in reducing VAs in ES. Definitive studies for SGB in VA management are needed. Study protocol: PROSPERO - registration number CRD42023430031.
Results of a one-year active-controlled study in pediatric patients (N=63) demonstrated negative effects of topiramate monotherapy on bone mineral acquisition via statistically significant decreases in bone mineral density (BMD) measured in lumbar spine and in total body less head [see Use in Specific Populations (8.4)]. Twenty-one percent of topiramate treated patients experienced clinically important reductions in BMD (Z score change from baseline of –0.5 or greater) compared to 0 patients in the control group. Although decreases in BMD occurred across all pediatric age subgroups, patients 6 to 9 years of age were most commonly affected. The sample size and study duration were too small to determine if fracture risk is increased. Decreased BMD in the lumbar spine was correlated with decreased serum bicarbonate, which commonly occurs with topiramate treatment and reflects metabolic acidosis, a known cause of increased bone resorption [see Warnings and Precautions (5.4)]. Although small decreases in some markers of bone metabolism (e.g., serum alkaline phosphatase, calcium, phosphorus, and 1,25-dihydroxyvitamin D) occurred in topiramate-treated patients, more significant decreases in serum parathyroid hormone and 25-hydroxyvitamin D, hormones involved in bone metabolism, were observed, along with an increased excretion of urinary calcium.
PURPOSE: To prepare an aq. foaming compsn. having a specific viscosity by formulating at least one specific water-soluble viscosity increasing agent into <=5 wt.% physiologically permissible amphiphilic foaming agent having a hydrophilic group and hydrophobic lipophilic group. CONSTITUTION: The aq. foaming compsn. is prepd. by formulating 5 wt.%, more adequately <=2 wt.% at least one physiologically permissible amphiphilic foaming agent having the hydrophilic group and hydrophobic lipophilic group, a polyol of edible quality having 2 to 25 hydroxy groups and a thickener composed of at least crosslinked polysaccharides. When this aq. foaming compsn. has a viscosity of >=5 cps at room temp. and forms a foam of a density <=0.2 consisting of fine air or gas bubbles sufficiently as stable as not to break when bubbled in the presence of gas or air.
The invention discloses brown sugar for treating dysmenorrhea and a preparation method of the brown sugar, belonging to the food field. The brown sugar is used for solving the problem that the brown sugar in the prior art is single in component and cannot be used for treating dysmenorrhea. The brown sugar comprises the following components in parts by weight: 30-100 parts of brown sugar, 10-50 parts of fruits of branchy paliurus, 10-50 parts of cassia twigs, 3-18 parts of nude pronephrium rhizome, 3-30 parts of girl flowers, 3-18 parts of northern bedstraw and 3-18 parts of cranberry tips. The preparation method of the brown sugar comprises the following steps: 1) weighing the fruits of branchy paliurus, the cassis twigs, the nude pronephrium rhizome, the girl flowers, the northern bedstraw and the cranberry tips, uniformly mixing and crushing the components, adding water into mixed powder to extract active ingredients, and then concentrating to obtain liquid medicine; 2) putting the brown sugar into the concentrated liquid medicine, stirring to dissolve the brown sugar bodies and homogenizing the mixture; and 3) spraying and drying to obtain the brown sugar powder for treating dysmenorrhea. The brown sugar disclosed by the invention comprises traditional Chinese medicine components for treating dysmenorrhea as well as traditional Chinese medicine components for treating irregular menstruation. The components are reasonably combined, so that the brown sugar disclosed by the invention has the effect of effectively treating dysmenorrhea.
PROBLEM TO BE SOLVED: To obtain a hair care product having suppressing effect of dandruff, itching and alopecia of head by using a solvent extract of eucalyptus of specific variety as an active ingredient. SOLUTION: Eucalyptusmacrocarpa of shrubby small-sized series distributed in the west of Australia is extracted with a solvent to afford a macrocarpa extract, which is then further purified by technique such as column chromatography to provide macrocarpals. This hair care product uses preferably especially macrocarpals (7 kinds of macrocarpals A to G). The blend ratio of the macrocarpa extract is about 0.1-10wt.% based on total amount of the hair care product. The hair care product includes e.g. gel, aerosol, hair pack, shampoo and rinse.
Participants will receive standard care include prenatal breastfeeding education at gestation of 24-36 weeks same as intervention group. They will not discuss about antenatal milk expression, breastfeeding self-efficacy and the effects of breastfeeding on GDM women.